A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

NCT01215968 · Completed

Last updated 2026-05-28

This study tests how a drug called LY2189265 affects the rate at which food and liquids leave the stomach in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 38 people

Who can join Ages 18–75 · all sexes

Timeline Started 2010-09 · est. completion 2011-07

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT01215968 ↗

Description as written by the study sponsor.

The primary purpose of this Study is to help answer the following research question(s). * How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes? * How does LY2189265 affect how the body handles metformin (a drug used to treat Type 2 diabetes)? * Is LY2189265 safe and are any side effects associated with it? The study will be participant-blind in Week 1, and participant- and investigator-blind from Week 2 through Week 5. Each participant will receive placebo on Week 1 and once-weekly doses of LY2189265 or Placebo on Weeks 2 to 5. Participants taking metformin for the treatment of Type 2 Diabetes Mellitus (T2DM) will continue taking metformin as part of the study.

Treatments tested

LY2189265 Biologic

1.5 mg administered subcutaneously
Placebo Drug

Administered subcutaneously

Main thing measured	Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01215968 ↗